(firstQuint)SGT-53 in Children With Recurrent or Progressive CNS Malignancies.

 This clinical trial is a early phase 1, open label, single center, single arm study of the combination of intravenously administered SGT-53 and irradiation and/or chemotherapy in pediatric patients with recurrent or progressive CNS malignancies.

 The objective of the study is to establish the safety and feasibility of administration of SGT-53 in conjunction with conventional radiotherapy and/or chemotherapy in children with recurrent or refractory CNS malignancies.

.

 SGT-53 in Children With Recurrent or Progressive CNS Malignancies@highlight

An early phase 1 for pediatric patients with recurrent or progressive CNS malignancies